The drug, Leqembi, may modestly slow cognitive decline in early stages of the disease but carries some safety risks. Still, data suggests it is more promising than the small number of other available treatments.
from NYT > Top Stories https://ift.tt/ETWkR0O
January 07, 2023 at 01:02AM
0 Comments